Jing-jing Xu

5-Year Clinical Outcomes of Successful Recanalisation for Coronary Chronic Total Occlusions in Patients With or Without Type 2 Diabetes Mellitus

Jing-jing Xu, B. Xu, Jin-qing Yuan, 2021, Frontiers in Cardiovascular Medicine.

The PRECISE-DAPT score and five-year outcomes after percutaneous coronary intervention: a large-scale, real-world study from China.

Fangchao Liu, Jing-jing Xu, B. Xu, 2021, European heart journal. Quality of care & clinical outcomes.

Interaction Between Treatment and Age or Sex in Non-ST-Segment Elevation Acute Coronary Disease and Three-Vessel Disease

R. Hui, K. Sun, Jing-jing Xu, 2022, Frontiers in Cardiovascular Medicine.

Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China

Jing-jing Xu, B. Xu, S. Qiao, 2021, Frontiers in Cardiovascular Medicine.

Novel polymorphism of the HMGCR gene related to the risk of diabetes in premature triple‐vessel disease patients

R. Hui, Jing-jing Xu, Keyong Huang, 2022, The journal of gene medicine.

Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention.

Zhan Gao, Jing-jing Xu, Xiaofang Tang, 2022, Atherosclerosis.

Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study

Jing-jing Xu, Jin-qing Yuan, Lin Jiang, 2022, Thrombosis Journal.

Prognostic impact of lipoprotein(a) in patients undergoing percutaneous coronary intervention modified by low density lipoprotein cholesterol.

Jing-jing Xu, Jin-qing Yuan, Xiaofang Tang, 2023, Clinica chimica acta; international journal of clinical chemistry.